Advancing Interdisciplinary Care in Prostate Cancer: Clinical Updates for Urology and Oncology Healthcare Professionals

This activity contains:

  • CME/CPE/CNE-Certified On-Demand Educational Activity

Released on: 9/21/2017

Expires on: 12/31/2017

Estimated completion time: 1 hour

Purpose
The goal of this activity is provide clinicians with the latest evidence-based information regarding individualized treatment for mCRPC, to be able to translate current and emerging evidence into real-world clinical practice.

Overview
Prostate cancer is the third leading cause of cancer death in men in the United States, accounting for 8% of all cancer deaths with an estimated 26,730 deaths in 2017. The recent development of novel hormonal agents, chemotherapy, and immunotherapy has dramatically changed the treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC). Until 2010, docetaxel was the only agent approved by the US Food and Drug Administration (FDA) to treat mCRPC. Sipuleucel-T and cabazitaxel were both FDA approved in 2010, followed by abiraterone acetate in 2011, enzalutamide in 2012, and most recently, radium-223 dichloride in 2013. With the approval of several new agents by the FDA in recent years, there are now multiple treatment options for patients with mCRPC, making clinical decision-making more difficult. There are also guideline recommendations published from the NCCN, American Urological Association (AUA), and American Society of Clinical Oncology (ASCO), which can contribute to variations in treatment approaches.

Additionally, treatment in an outpatient, office-based setting may result in cost savings compared to both hospital inpatient and outpatient settings. Other advantages include safe and easy drug administration, avoidance of hospitalization, familiarity with a particular facility, enhanced physical comfort, and improved psychological well being.

This activity will review available therapies for mCRPC, selecting and sequencing individualized therapy, treatment guidelines, and considerations for treatment in the outpatient setting.

Activity Agenda

  • Activity Overview (5 min)
  • Available Therapies for mCRPC (20 min)
  • Selecting and Sequencing Therapy for Individualized Approaches (15 min)
  • Expert Commentary – Providing Treatment for Advanced Prostate Cancer in the Outpatient Setting, Advice for Urology Professionals (15 min)

Target Audience

This activity is intended for genitourinary oncologists, medical oncologists, urologists, radiation oncologists, oncology and urology nurses, fellows, and pharmacists.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Analyze efficacy and safety data of currently available therapy for the treatment of mCRPC to select and sequence therapy
  • Develop individualized treatment strategies consistent with current guidelines for patients with mCRPC based on patient- and disease-related characteristics
  • Assess the benefits of office-based treatment for patients with mCRPC as a mechanism to provide enhanced care coordination to optimize patient outcomes
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 Attendance
Course opens: 
09/21/2017
Course expires: 
12/31/2017
Cost:
$0.00
Rating: 
0
Faculty 

A. Oliver Sartor, MD
Medical Director
Tulane Cancer Center
Assistant Dean for Oncology
Tulane University Medical School
New Orleans, LA


Physician Continuing Medical Education

Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit (UAN 0592-0000-17-033-H01-P).

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information
For information about the certification of this activity, please contact AXIS at info@axismeded.com

Method of Participation
There are no fees for participating and receiving CME/CPE/CNE credit for this activity. Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, within an electronic portal, your certificate will be made available immediately. Pharmacists will enter their NABP ID/MMDD and birth and your record will be uploaded to CPE Monitor. Instructions to the electronic portal will be provided.

Disclosure of Conflict of Interest 
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterReported Financial Relationship
A. Oliver Sartor, MD

A. Oliver Sartor, MD, reported a financial interest/relationship or affiliation in the form of: Consultant, AstraZeneca, Bayer, Bellicum, Bristol-Myers Squibb, Celgene, Dendreon, EMD Serono, Johnson & Johnson, Medivation, Oncogenex, Sanofi-Aventis, Tokai; Grant/Research support: Bayer, Endocyte, Innocrin, Johnson & Johnson, Sanofi-Aventis.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda-Gracie-King, MS, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Stephanie Sutphin, PharmD reports a financial interest/relationship or affiliation in the form of Advisory board: Seattle Genetics and Amgen Biosimilars

Media System Requirements
PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*   
MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Safeguards Against Commercial Bias   
AXIS Medical Education affirms that the content and format of the certified activity and its related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, AXIS employs several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for certified activities to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation guidelines, and resolution of any actual or perceived conflicts of interest that exist.
We employ several metrics during review of content materials, including:

  • 1. Fair balance

a. Recommendations must be based on a reasonable and valid interpretation of the information available on the subject matter.
b. No single product or service is overrepresented when other equal, competing products or services are available for inclusion.

  • 2. Scientific objectivity of studies mentioned in the activity or used as the basis for content development.

This activity is supported by an educational grant from Sanofi Genzyme.

There is no fee for this educational activity.

Jointly provided by

AXIS 1555 WebArchive

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 Attendance

Accreditation Period

Course opens: 
09/21/2017
Course expires: 
12/31/2017

Price

Cost:
$0.00
Please login or register to take this course.